[go: up one dir, main page]

AR090352A1 - Anticuerpos frente a los ligandos del receptor b1 de bradicinina - Google Patents

Anticuerpos frente a los ligandos del receptor b1 de bradicinina

Info

Publication number
AR090352A1
AR090352A1 ARP130100847A AR090352A1 AR 090352 A1 AR090352 A1 AR 090352A1 AR P130100847 A ARP130100847 A AR P130100847A AR 090352 A1 AR090352 A1 AR 090352A1
Authority
AR
Argentina
Prior art keywords
calidine
des
arg10
antibodies
present
Prior art date
Application number
Other languages
English (en)
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49261064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR090352(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR090352A1 publication Critical patent/AR090352A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/18—Kallidins; Bradykinins; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Zoology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente proporciona anticuerpos que se unen específicamente a calidina o des-Arg₁₀-calidina La presente proporciona también composiciones farmacéuticas, así como ácido nucleicos que codifican anticuerpos anti-calidina o anti des-Arg₁₀-calidina vectores de expresión recombinantes y células hospedantes para producir dichos anticuerpos, o fragmentos de los mismos. También son proporcionados por la presente métodos de uso de los anticuerpos de la presente para modular la actividad de la calidina o des-Arg₁₀-calidina o para detectar la calidina o la des-Arg₁₀-calidina ya sea in vitro o in vivo. La presente proporciona además métodos para producir anticuerpos que se unen específicamente a des-Arg₉-bradicinina y a un péptido tipo des-Arg₁₀-calidina.
ARP130100847 2012-03-28 2013-03-15 Anticuerpos frente a los ligandos del receptor b1 de bradicinina AR090352A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261616845P 2012-03-28 2012-03-28
FR1350953 2013-02-04

Publications (1)

Publication Number Publication Date
AR090352A1 true AR090352A1 (es) 2014-11-05

Family

ID=49261064

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100847 AR090352A1 (es) 2012-03-28 2013-03-15 Anticuerpos frente a los ligandos del receptor b1 de bradicinina

Country Status (38)

Country Link
US (5) US9376494B2 (es)
EP (2) EP3246339B1 (es)
JP (5) JP6779012B2 (es)
KR (4) KR102367723B1 (es)
CN (3) CN113773385B (es)
AR (1) AR090352A1 (es)
AU (2) AU2013240242B2 (es)
BR (1) BR112014024282A2 (es)
CA (1) CA2868353C (es)
CL (2) CL2014002590A1 (es)
CO (1) CO7111293A2 (es)
CR (1) CR20140440A (es)
CY (1) CY1121466T1 (es)
DK (2) DK2831113T3 (es)
DO (1) DOP2014000199A (es)
EA (1) EA201491784A1 (es)
ES (1) ES2673869T3 (es)
GT (1) GT201400192A (es)
HR (1) HRP20180928T1 (es)
HU (1) HUE037720T2 (es)
IL (1) IL234830B (es)
LT (1) LT2831113T (es)
MA (1) MA37407B1 (es)
MX (2) MX361874B (es)
MY (2) MY166157A (es)
NZ (1) NZ631543A (es)
PE (1) PE20142170A1 (es)
PH (1) PH12014501970A1 (es)
PL (1) PL2831113T3 (es)
PT (1) PT2831113T (es)
RS (1) RS57413B1 (es)
SG (2) SG11201405162YA (es)
SI (1) SI2831113T1 (es)
TR (1) TR201808486T4 (es)
TW (1) TWI605060B (es)
UA (1) UA117097C2 (es)
UY (1) UY34682A (es)
WO (1) WO2013148296A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102367723B1 (ko) * 2012-03-28 2022-02-28 사노피 브라디키닌 b1 수용체 리간드에 대한 항체
CU24446B1 (es) 2013-03-13 2019-10-04 Prothena Biosciences Ltd Un anticuerpo monoclonal humanizado que se une a tau
CN105504049B (zh) * 2014-09-26 2019-07-05 艾托金生物医药（苏州）有限公司 宫颈癌相关的hpv e7蛋白单克隆抗体及其应用
IL322971A (en) 2015-12-15 2025-10-01 Takeda Pharmaceuticals Co Method for evaluating the efficacy of a drug for a plasma kallikrein-mediated disorder
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
PL3452507T3 (pl) 2016-05-02 2023-01-09 Prothena Biosciences Limited Immunoterapia tau
MY197413A (en) 2016-05-02 2023-06-16 Prothena Biosciences Ltd Antibodies recognizing tau
BR112018072389A2 (pt) 2016-05-02 2019-02-19 Prothena Biosciences Limited anticorpos que reconhecem tau
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
BR112019022906A2 (pt) 2017-05-02 2020-05-26 Prothena Biosciences Limited Anticorpos que reconhecem tau
BR112019023111A2 (pt) * 2017-05-08 2020-07-28 Adimab, Llc domínios de ligação anti-cd3 e anticorpos compreendendo os mesmos, e métodos para sua geração e uso
WO2019148186A1 (en) * 2018-01-29 2019-08-01 Silarus Therapeutics, Inc. Antibodies binding erfe and methods of use
CU20210073A7 (es) 2019-03-03 2022-04-07 Prothena Biosciences Ltd Anticuerpos que se unen dentro de la región de unión a microtúbulos de tau definida por cdrs
CN119306824B (zh) * 2024-10-08 2025-09-26 江苏埃尔迪生物科技有限公司 一种全价展示scFv的通用型M13噬菌体探针及其构建方法和应用

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
DE68921982T4 (de) 1988-06-14 1996-04-25 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
CA2078689C (en) 1990-03-20 2003-02-11 Sherie L. Morrison Chimeric antibodies with receptor binding ligands in place of their constant region
JPH09506761A (ja) 1990-11-09 1997-07-08 ステファン ディー．ギリーズ サイトカインの免疫複合体
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
DE69738522T2 (de) 1996-08-02 2009-04-02 Bristol-Myers Squibb Co. Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ATE319745T1 (de) 1997-05-21 2006-03-15 Biovation Ltd Verfahren zur herstellung von nicht-immunogenen proteinen
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
AU770555B2 (en) 1998-08-17 2004-02-26 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
CA2342967A1 (en) 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
EP1141024B1 (en) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
EP1487879B1 (en) 2002-03-01 2012-12-26 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
ES2381617T5 (es) 2002-08-14 2016-02-24 Macrogenics, Inc. Anticuerpos específicos frente a FcgammaRIIB y sus procedimientos de uso
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
ATE480562T1 (de) 2002-10-15 2010-09-15 Facet Biotech Corp Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
BRPI0506771A (pt) 2004-01-12 2007-05-22 Applied Molecular Evolution anticorpo, e, composição farmacêutica
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
CN103172731A (zh) 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
RU2007147938A (ru) * 2005-06-14 2009-07-20 Цитос Биотехнологи Аг (Ch) Конъюгаты антигенов и их применение
US7833260B2 (en) 2006-07-20 2010-11-16 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
AU2007334264A1 (en) * 2006-11-15 2008-06-26 Medarex, Inc. Human monoclonal antibodies to BTLA and methods of use
WO2008151204A1 (en) 2007-06-04 2008-12-11 Sequent Medical Inc. Methods and devices for treatment of vascular defects
SG182192A1 (en) * 2007-06-12 2012-07-30 Ac Immune Sa Humanized antibodies to amyloid beta
MX2010001975A (es) 2007-08-29 2010-03-10 Sanofi Aventis Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso.
CN101888856B (zh) * 2007-11-07 2014-08-27 塞尔德克斯医疗公司 结合人树突和上皮细胞205(dec-205)的抗体
EP2420245A1 (en) * 2010-08-18 2012-02-22 Max-Delbrück-Centrum Für Molekulare Medizin Therapeutic use of agonists or antagonists of bradykinin receptor 1 or 2, for modulation collateral blood vessel growth
KR102367723B1 (ko) * 2012-03-28 2022-02-28 사노피 브라디키닌 b1 수용체 리간드에 대한 항체

Also Published As

Publication number Publication date
CL2014002590A1 (es) 2015-01-16
JP2021166538A (ja) 2021-10-21
DK2831113T3 (en) 2018-06-25
KR20200121370A (ko) 2020-10-23
BR112014024282A2 (pt) 2017-08-08
ES2673869T3 (es) 2018-06-26
CL2017003039A1 (es) 2018-03-16
US9376494B2 (en) 2016-06-28
CN113773385B (zh) 2025-09-12
IL234830B (en) 2018-11-29
JP7411609B2 (ja) 2024-01-11
JP2015513903A (ja) 2015-05-18
US20230399388A1 (en) 2023-12-14
US20160368976A1 (en) 2016-12-22
CN104334578A (zh) 2015-02-04
CO7111293A2 (es) 2014-11-10
HRP20180928T1 (hr) 2018-07-27
DOP2014000199A (es) 2014-10-31
SG10201702396QA (en) 2017-04-27
AU2013240242B2 (en) 2018-02-08
JP2019050822A (ja) 2019-04-04
CR20140440A (es) 2014-11-17
MA37407A1 (fr) 2016-05-31
KR102367723B1 (ko) 2022-02-28
AU2013240242A1 (en) 2014-10-02
MX2014011688A (es) 2015-01-22
KR102035882B1 (ko) 2019-10-24
TR201808486T4 (tr) 2018-07-23
PT2831113T (pt) 2018-06-20
US20150050270A1 (en) 2015-02-19
MY166157A (en) 2018-06-06
SG11201405162YA (en) 2014-09-26
KR20150002679A (ko) 2015-01-07
CA2868353C (en) 2023-10-31
KR102166083B1 (ko) 2020-10-16
CN104334578B (zh) 2021-10-08
PL2831113T3 (pl) 2018-08-31
JP6779012B2 (ja) 2020-11-04
CA2868353A1 (en) 2013-10-03
KR20220031728A (ko) 2022-03-11
WO2013148296A1 (en) 2013-10-03
AU2018203081A1 (en) 2018-05-24
EP2831113A1 (en) 2015-02-04
MA37407B1 (fr) 2018-03-30
US20180222967A1 (en) 2018-08-09
NZ631543A (en) 2017-03-31
HUE037720T2 (hu) 2018-09-28
SI2831113T1 (en) 2018-08-31
EP3246339A1 (en) 2017-11-22
CY1121466T1 (el) 2020-05-29
HK1206754A1 (en) 2016-01-15
US9879079B2 (en) 2018-01-30
JP6912441B2 (ja) 2021-08-04
CN113773385A (zh) 2021-12-10
TWI605060B (zh) 2017-11-11
DK3246339T3 (da) 2020-01-27
US10465002B2 (en) 2019-11-05
MY184037A (en) 2021-03-17
EP2831113B1 (en) 2018-03-14
MX2018015914A (es) 2021-12-08
KR20190121861A (ko) 2019-10-28
US20200115441A1 (en) 2020-04-16
UY34682A (es) 2013-10-31
PH12014501970A1 (en) 2014-11-17
LT2831113T (lt) 2018-06-25
GT201400192A (es) 2015-07-29
UA117097C2 (uk) 2018-06-25
MX361874B (es) 2018-12-18
EA201491784A1 (ru) 2015-02-27
RS57413B1 (sr) 2018-09-28
TW201343671A (zh) 2013-11-01
JP2024038036A (ja) 2024-03-19
JP2025134874A (ja) 2025-09-17
PE20142170A1 (es) 2015-01-07
EP3246339B1 (en) 2019-10-09
CN120441698A (zh) 2025-08-08

Similar Documents

Publication Publication Date Title
AR090352A1 (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
MX2019008803A (es) Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos.
EA201592269A1 (ru) Способы и композиции для снижения иммуносупрессии опухолевыми клетками
MX2014008963A (es) Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina.
CR20150258A (es) Anticuerpos anti-ceacam5 y usos de éstos
CO6680702A2 (es) Péptido o complejo péptido que se une a integrina alfa 2 y metodos y sus usos que implican a los mismos
MX2015010836A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno anti egfrviii humanizado.
MX392416B (es) Métodos y composiciones para terapia celular adoptiva.
MY175708A (en) Dna antibody constructs and method of using same
MX2016007063A (es) Peptidos terapeuticos.
NZ700823A (en) Antibodies against claudin 18.2 useful in cancer diagnosis
UY33588A (es) Moleculas de union a vegf
ECSP14020402A (es) Polipéptidos de unión a cx3cr1
ECSP14013132A (es) Anticuerpos anti-psgl-1 y usos de los mismos
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
PE20160528A1 (es) Anticuerpos
EA201991409A2 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
CL2012003458A1 (es) Vector que comprende un polipeptido antigénico de campylobacter; composicion farmacéutica que comprende dicho vector; uso del vector para mejorar respuesta inmune del sujeto al polipéptido antigénico.
AR080680A1 (es) Proteinas de union a basigina
UY34662A (es) Acido nucleico y proteina recombinante del gen de la toxina axmi335, vectores, células, composiciones y métodos para proteger plantas
MX377995B (es) Moléculas de unión al receptor bag3 para uso como un medicamento.
ECSP14024494A (es) Anticuerpos frente a los Ligandos del receptor B1 de bradicinina
PH12014502182A1 (en) Methods and compositions for modulating notch activity
TN2014000395A1 (en) Antibodies to bradykinin b1 receptor ligands
EA201792665A1 (ru) Антитела против ctla-4 и способы их применения

Legal Events

Date Code Title Description
FB Suspension of granting procedure